Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
CBST > SEC Filings for CBST > Form 8-K on 10-Sep-2013All Recent SEC Filings

Show all filings for CUBIST PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for CUBIST PHARMACEUTICALS INC


10-Sep-2013

Entry into a Material Definitive Agreement, Creation of a Direct Finan


Item 1.01 Entry into a Material Definitive Agreement

Indentures and the Notes

On September 10, 2013, Cubist Pharmaceuticals, Inc. (the "Company") issued $350 million aggregate principal amount of 1.125% Convertible Senior Notes due 2018 (the "2018 Notes") and $450 million aggregate principal amount of 1.875% Convertible Senior Notes due 2020 (the "2020 Notes" and, together with the 2018 Notes, the "Notes") pursuant to their respective Indentures, dated as of September 10, 2013 (each an "Indenture" and, together, the "Indentures"), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee. The 2018 Notes will pay interest semi-annually on each March 1 and September 1 at an annual rate of 1.125%, and will mature on September 1, 2018 unless earlier converted or repurchased. The 2020 Notes will pay interest semi-annually on each March 1 and September 1 at an annual rate of 1.875%, and will mature on September 1, 2020 unless earlier converted or repurchased. The Notes will be convertible, subject to certain conditions, into cash, shares of common stock of the Company, or a combination of cash and shares of common stock, at the Company's option (subject to, and in accordance with, the settlement provisions of the applicable Indenture). The initial conversion rate for both the 2018 Notes and the 2020 Notes will be 12.1318 shares of common stock (subject to adjustment as provided for in the applicable Indenture) per $1,000 principal amount of the Notes, which is equal to an initial conversion price of approximately $82.43 per share, representing a conversion premium of approximately 32.5% above the closing price of the common stock of $62.21 per share on September 4, 2013.

Holders of the Notes of a series may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding March 1, 2018, in the case of the 2018 Notes, and March 1, 2020, in the case of the 2020 Notes, in multiples of $1,000 principal amount, only under the following circumstances:

during any calendar quarter commencing after the calendar quarter ending on December 31, 2013 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for such series on each applicable trading day;

during the five business day period after any five consecutive trading day period (the ''measurement period'') in which the ''trading price'' (as defined in the applicable Indenture) per $1,000 principal amount of Notes of such series for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate for such series on each such trading day; or

upon the occurrence of specified corporate events described in the applicable Indenture.

On or after March 1, 2018 until the close of business on the second scheduled trading day immediately preceding September 1, 2018, holders may convert their 2018 Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances. On or after March 1, 2020 until the close of business on the second scheduled trading day immediately preceding September 1, 2020, holders may convert their 2020 Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances.

If the Company experiences a fundamental change, as described in the applicable Indenture, prior to the relevant maturity date of the Notes, holders of the Notes will, subject to specified conditions, have the right, at their option, to require the Company to repurchase for cash all or a portion of their Notes at a repurchase price equal to 100% of the principal amount of the relevant series of Notes to be repurchased, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the relevant maturity date of the Notes, the Company will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event.

Each Indenture provides for customary events of default. In the case of an event of default with respect to a series of Notes arising from specified events of bankruptcy or insolvency, all outstanding Notes of such series will


become due and payable immediately without further action or notice. If any other event of default with respect to a series of Notes under the applicable Indenture occurs or is continuing, the Trustee or holders of at least 25% in aggregate principal amount of the then outstanding Notes of such series may declare the principal amount of the Notes of such series to be immediately due and payable.

In certain circumstances if, at any time during the six-month period beginning on, and including, the date that is six months after the last date of original issuance of the Notes, the Company fails to timely file certain documents or reports required under the Securities Exchange Act of 1934, as amended, or the Notes are not otherwise freely tradable by holders of the Notes other than the Company's affiliates, additional interest will accrue on the Notes during the . . .



Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.



Item 3.02 Unregistered Sales of Equity Securities

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

As described in Item 1.01 of this Current Report on Form 8-K, on September 5, 2013, the Company entered into additional warrant transactions with each of the Option Counterparties. Pursuant to the additional warrant transactions, the Company issued 1,213,182 warrants with a strike price of $96.43 per share. The number of shares issuable upon exercise of the warrants and the strike price are subject to adjustment under certain circumstances described in the additional warrant transaction confirmations. The Company offered and sold the warrants in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. Neither the warrants nor the underlying shares of common stock (issuable in the event the market price per share of the common stock exceeds the strike price of the warrants on the date the warrants are exercised) have been registered under the Securities Act. Neither the warrants nor such underlying shares of common stock may be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

As described in Item 1.01 of this Current Report on Form 8-K, on September 10, 2013, the Company issued $350 million aggregate principal amount of 2018 Notes and $450 million aggregate principal amount of 2020 Notes to the Initial Purchasers in a private placement pursuant to exemptions from the registration requirements of the Securities Act. The Company offered and sold the Notes to the Initial Purchasers of the Notes in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, for resale by such Initial Purchasers to "qualified institutional buyers" pursuant to the exemption from registration provided by Rule 144A under the Securities Act. The Notes have not been registered under the Securities Act. The Notes are convertible into cash, shares of the Company's common stock, or a combination thereof, as described in this Current Report on Form 8-K.



Item 8.01 Other Events

On September 10, 2013, the Company issued a press release announcing the closing of its offering of the Notes.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

4.1 Indenture, dated as of September 10, 2013, between Cubist Pharmaceuticals, Inc. and the Bank of New York Mellon Trust Company, N.A.
(including the form of the 1.125% Convertible Senior Note due 2018)

4.2 Indenture, dated as of September 10, 2013, between Cubist Pharmaceuticals, Inc. and the Bank of New York Mellon Trust Company, N.A.
(including the form of the 1.875% Convertible Senior Note due 2020)


4.3     Form of 2018 Note (included in Exhibit 4.1)

4.4     Form of 2020 Note (included in Exhibit 4.2)

10.1    Additional convertible bond hedge transaction confirmation, dated as of
        September 5, 2013, by and between Morgan Stanley & Co. International plc
        and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible
        Senior Notes due 2018

10.2    Additional convertible bond hedge transaction confirmation, dated as of
        September 5, 2013, by and between Barclays Bank PLC and Cubist
        Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes
        due 2018

10.3    Additional convertible bond hedge transaction confirmation, dated as of
        September 5, 2013, by and between Royal Bank of Canada and Cubist
        Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes
        due 2018

10.4    Additional issuer warrant transaction confirmation, dated as of
        September 5, 2013, by and between Morgan Stanley & Co. International plc
        and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible
        Senior Notes due 2018

10.5    Additional issuer warrant transaction confirmation, dated as of
        September 5, 2013, by and between Barclays Bank PLC and Cubist
        Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes
        due 2018

10.6    Additional issuer warrant transaction confirmation, dated as of
        September 5, 2013, by and between Royal Bank of Canada and Cubist
        Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes
        due 2018

10.7    Additional convertible bond hedge transaction confirmation, dated as of
        September 5, 2013, by and between Morgan Stanley & Co. International plc
        and Cubist Pharmaceuticals, Inc., in reference to the 1.875% Convertible
        Senior Notes due 2020

10.8    Additional convertible bond hedge transaction confirmation, dated as of
        September 5, 2013, by and between Barclays Bank PLC and Cubist
        Pharmaceuticals, Inc., in reference to the 1.875% Convertible Senior Notes
        due 2020

10.9    Additional convertible bond hedge transaction confirmation, dated as of
        September 5, 2013, by and between Royal Bank of Canada and Cubist
        Pharmaceuticals, Inc., in reference to the 1.875% Convertible Senior Notes
        due 2020

10.10   Additional issuer warrant transaction confirmation, dated as of
        September 5, 2013, by and between Morgan Stanley & Co. International plc
        and Cubist Pharmaceuticals, Inc., in reference to the 1.875% Convertible
        Senior Notes due 2020

10.11   Additional issuer warrant transaction confirmation, dated as of
        September 5, 2013, by and between Barclays Bank PLC and Cubist
        Pharmaceuticals, Inc., in reference to the 1.875% Convertible Senior Notes
        due 2020

10.12   Additional issuer warrant transaction confirmation, dated as of
        September 5, 2013, by and between Royal Bank of Canada and Cubist
        Pharmaceuticals, Inc., in reference to the 1.875% Convertible Senior Notes
        due 2020

99.1    Press Release dated September 10, 2013.


  Add CBST to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for CBST - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.